Furthermore, isorhamnetin suppresses the NF-κB pathway activation, which decreases pro-inflammatory cytokines such as IL-6 and TNF-α and decreases EMT, avoiding cancer cell migration and metastasis [156,251]. Here, NFKB1 is linked to cancer.